Dose-dependent Antifibrotic Effect of Polysaccharide from Mycelium of Ganoderma Lucidum on Liver Biliary Cirrhosis in Rats

담도결찰 흰쥐에서 영지배양 균사체 유래 다당체의 항섬유화 효과 검색 및 용량의존성시험

  • Park, Eun-Jeon (Medicinal Resources Research Center, College of Pharmacy, Wonkwang University) ;
  • Ko, Geon-Il (Medicinal Resources Research Center, College of Pharmacy, Wonkwang University) ;
  • Kim, Jae-Baek (Medicinal Resources Research Center, College of Pharmacy, Wonkwang University) ;
  • Sohn, Dong-Hwan (Medicinal Resources Research Center, College of Pharmacy, Wonkwang University)
  • 박은전 (원광대학교 약학대학, 의약자원연구센터) ;
  • 고건일 (원광대학교 약학대학, 의약자원연구센터) ;
  • 김재백 (원광대학교 약학대학, 의약자원연구센터) ;
  • 손동환 (원광대학교 약학대학, 의약자원연구센터)
  • Published : 1997.04.01

Abstract

This study was carried out to investigate the dose dependent antifibrotic effects of polysaccharide from mycelium of Ganoderma lucidum. The experimental hepatic cirrhosis was induced by bile duct ligation/scission (BDL/S) in rats. BDL/S rats in each group were dosed 0.5 mg, 2.0 mg, 5.0 mg or 10.O mg/rat/day orally for 4 weeks after the operation. Antifibrotic effects were evaluated by serum biochemical values, hydroxyproline contents, and light microscopical histology. The results obtained were as follows: 1) Hydroxyproline contents in liver of 5.0 and 10.0mg polysaccharide-treated BDL/S rats were significantly reduced 2) In serum test, ALT, AST, ALP values in polysaccharide from Ganoderma lucidum-treated group were lower than BDL/S control group 3) The hepatic damage such as hepatocellular necrosis, inflammation, bile duct proliferation and fibrosis was less severe in the livers of 2.0 mg and 5.0 mg polysaccharide-treated rats. These results suggest that polysaccharide from mycelium of Ganoderma lucidum to be a promising agent for the inhibition of hepatic cirrhosis.

Keywords

References

  1. 中藥大事典 上海科學技術出版社 小學館
  2. J. Clin Pathol. v.31 The morphology of cirrhosis Anthony, P. P.;Ishak, K. G.;Nayak, N. G.;Poulsen, H. E.;Schener, P. J.;Sobin, L. H.
  3. Disease of the liver and biliary system(8th ed.) Sherlock, S.
  4. Hepatol. v.8 Therapeutic strategies for hepatic fibrosis Chojkier, M.;Brenner, D. A.
  5. 한국임상약학회지 v.3 실험적 간장해에 대한 WY-91제제의 영향 한상수;손동환;김재백
  6. 원광대학교 약품연구소보 v.7 Biliary liver fibrosis 실험동물에서 인삼, 영지, 오미자의 항섬유화 약효검색 김기영;한상수;김재백
  7. Anal. Biochem. v.112 A simple method to determine nanogram levels of 4-hydroxyproline in biological tissue Jamall, I. S.;Finelli, V. N.;Que Hee, S. S.
  8. J. Hepatol. v.13 Connective tissue polypeptides in serum as parameters ot monitor antifibrotic treatment in hepatic fibrogenesis Schuppan, D.
  9. 한국실험동물학회지 v.9 남도손상 수술방법을 이용한 랫드에서 간섬유화(경화) 실험동물 모델의 확립 김기영;Schuppan, D.;김재백
  10. Hepatol. v.3 Is cirrhosis of the liver experimentally produced by CCl₄an adequate model of human cirrhosis? Tamayo, R. P.
  11. Br. J. Exp. Path. v.65 Prolonged bile duct obstruction : a new experimental model for cirrhosis in the rat Kountouras, J.;Billing, B. H.;Scheuder, P. J.
  12. Hepatol. v.7 Effectiveness of colchicine in patients with cirrhosis[abstract] Kershenobich, H. D.;Vargas, F.;Garcia-Tsao, G.;Perez-Tamayo, R.;Rojkind, M.
  13. Disease of the liver and biliary systdem(8th ed.) Sherlock S.
  14. Gastroenterol. v.86 Glucocorticoids suppress formation of collagen by the hepatocyte: Studies in primary monolayer cultures of parenchymal cells prepared from adult rat liver Guzelian, D. S.;Lindblad, W. J.;Diegelmann, R. F.
  15. J. Lab. Clin. Med. v.113 Preventive effect of malotilate on dimethy-lnitrosamine-induced liver fibrosis in the rat Ala-Kokko, L.;Stenback, F.;ryhanen, L.
  16. J. Hepatol. v.13 Fibrosis of the liver in rats induced by bile duct ligation:Effects of in hibition of prolyl 4-hydroxylase Boker, K.;Schwarting, G.;Kaule, G.;Gunzler, V.;Schmidt, E.
  17. Hepatol. v.18 Interferon-gamma reduces liver injury and collagen deposition in dimethylni-trosamine-induced cirrhosis [abstract] Svegliati Beroni, G.;Curto, P.;Recchioni, A.;Mancini, R.;Benedetti, A.;Jezequel, A. ㅡ.;ㅒ기무야, ㄹ.